

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT										
NATURE OF CONVEYANCE:	ASSIGNMENT										
CONVEYING PARTY DATA											
<table border="1"> <thead> <tr> <th>Name</th> <th>Execution Date</th> </tr> </thead> <tbody> <tr> <td>John Vincent Calienni</td> <td>10/20/2011</td> </tr> <tr> <td>Guang-Pei Chen</td> <td>10/22/2011</td> </tr> <tr> <td>Baoqing Gong</td> <td>10/20/2011</td> </tr> <tr> <td>Prasad Koteswara Kapa</td> <td>10/20/2011</td> </tr> </tbody> </table>		Name	Execution Date	John Vincent Calienni	10/20/2011	Guang-Pei Chen	10/22/2011	Baoqing Gong	10/20/2011	Prasad Koteswara Kapa	10/20/2011
Name	Execution Date										
John Vincent Calienni	10/20/2011										
Guang-Pei Chen	10/22/2011										
Baoqing Gong	10/20/2011										
Prasad Koteswara Kapa	10/20/2011										
RECEIVING PARTY DATA											
<table border="1"> <tr> <td>Name:</td> <td>Novartis Pharmaceuticals Corporation</td> </tr> <tr> <td>Street Address:</td> <td>One Health Plaza</td> </tr> <tr> <td>City:</td> <td>East Hanover</td> </tr> <tr> <td>State/Country:</td> <td>NEW JERSEY</td> </tr> <tr> <td>Postal Code:</td> <td>07936</td> </tr> </table>		Name:	Novartis Pharmaceuticals Corporation	Street Address:	One Health Plaza	City:	East Hanover	State/Country:	NEW JERSEY	Postal Code:	07936
Name:	Novartis Pharmaceuticals Corporation										
Street Address:	One Health Plaza										
City:	East Hanover										
State/Country:	NEW JERSEY										
Postal Code:	07936										
PROPERTY NUMBERS Total: 1											
<table border="1"> <thead> <tr> <th>Property Type</th> <th>Number</th> </tr> </thead> <tbody> <tr> <td>Application Number:</td> <td>13882353</td> </tr> </tbody> </table>		Property Type	Number	Application Number:	13882353						
Property Type	Number										
Application Number:	13882353										
CORRESPONDENCE DATA											
Fax Number: <i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i> Phone: 8627780705 Email: cindy.klepacky@novartis.com Correspondent Name: Cindy Klepacky Address Line 1: One Health Plaza Address Line 4: East Hanover, NEW JERSEY 07936											
ATTORNEY DOCKET NUMBER:	PAT054441-US-PCT										
NAME OF SUBMITTER:	Cindy Klepacky										
Signature:	/Cindy Klepacky/										

Date:

05/01/2013

Total Attachments: 10

source=Inventors_to_Novartis_Pharmaceutucals_Corporation#page1.tif
source=Inventors_to_Novartis_Pharmaceutucals_Corporation#page2.tif
source=Inventors_to_Novartis_Pharmaceutucals_Corporation#page3.tif
source=Inventors_to_Novartis_Pharmaceutucals_Corporation#page4.tif
source=Inventors_to_Novartis_Pharmaceutucals_Corporation#page5.tif
source=Inventors_to_Novartis_Pharmaceutucals_Corporation#page6.tif
source=Inventors_to_Novartis_Pharmaceutucals_Corporation#page7.tif
source=Inventors_to_Novartis_Pharmaceutucals_Corporation#page8.tif
source=Inventors_to_Novartis_Pharmaceutucals_Corporation#page9.tif
source=Inventors_to_Novartis_Pharmaceutucals_Corporation#page10.tif

ASSIGNMENT

This Assignment Agreement is entered into by and between:

- 1) John Vincent CALIENNI, c/o Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover NJ 07936 United States of America, a citizen of the United States of America
- 2) Guang-Pei CHEN, 33 Preston Drive, Livingston, NJ 07039 United States of America, a citizen of the United States of America,
- 3) Baoqing GONG, c/o Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover NJ 07936 United States of America, a citizen of the United States of America;
- 4) Prasad Kotswara KAPA, c/o Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover NJ 07936 United States of America, a citizen of the United States of America;

(hereinafter "Inventor(s)"), and Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover NJ 07936, United States of America, a company organized under the laws of Delaware.

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, I/We the Inventor(s) do hereby confirm and agree that, by operation of law and/or contract, and/or by the fulfillment of any and all legal requirements regarding the transfer of employee inventions in my/our country of employment, Novartis Pharmaceuticals Corporation, is the true and lawful owner of all right, title and interest in all inventions, discoveries, patents/utility models, applications, and rights described in paragraphs (1) through (8) below.

If, however, under the laws of any country, I/We the Inventor(s) nevertheless have any ownership right, title or interest in any of the items described herein (which I/We do not believe to be the case and make no claim in or to), for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, I/We the Inventor(s) do hereby sell, assign and transfer to Novartis Pharmaceuticals Corporation and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of our right, title and interest for all countries of the world in and to

(1) all of our inventions and discoveries described in the provisional or non-provisional patent, utility model, or other application(s) entitled

SALT(S) OF 7-CYCLOPENTYL-2-(5-PIPERAZIN-1-YL-PYRIDIN-2-YLAMINO)-7H-PYRROLO[2,3-D]PYRIMIDINE-6-CARBOXYLIC ACID DIMETHYLAMIDE AND PROCESSES OF MAKING THEREOF

and filed in the Office on , 20 and accorded Application Number
and/or filed as a PCT International Application on , 20 and accorded International
Patent Application Number PCT/ ; and/or filed in the United States Patent and Trademark
Office on 10 November 2010 and accorded Application Number 61/412,064

(2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);

(3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees or in our/my name, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

(4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);

(5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;

(6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;

(7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;

(8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said

patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by me/us if this sale, assignment and transfer had not been made.

I/We the Inventor(s) hereby authorize ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s) and Application Number(s) of said patent, utility model, or other application(s) when notified thereof.


I/We the Inventor(s) hereby covenant and agree that I/We will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE.

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment shall be governed by the laws of Delaware.


Assignment is effective as from the earliest priority date as stated above.

Executed this 20 day of Oct, 2011


L.S.
John Vincent CALIENNI

Witness

Print Name: NANESHVAR SAWANT.



Witness

Print Name: MAUREEN M'GEE

Executed this day of , 20.

L.S.
Guang-Pei CHEN


Witness

Print Name:

Witness

Print Name:

Executed this 20 day of Oct, 2011


L.S.
Baoqing GONG

Witness

Print Name: NANESHVAR SAWANT.



Witness

Print Name: MAUREEN M'GEE

Executed this 20 day of Oct, 2011

Prasad Koteswara KAPA L.S.
Prasad Koteswara KAPA

Witness

Print Name: WANDSHAWA SAWANT

Witness

Print Name: MAUREEN M'GEE

Executed this 7th day of Nov, 2011.

Novartis Pharmaceuticals Corporation

BY Lydia McNally L.S.
Lydia McNally

Witness

Print Name Linda Subinaccio

Witness

Print name Maureen McGee

ASSIGNMENT

This Assignment Agreement is entered into by and between:

- 1) John Vincent CALIENNI, c/o Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover NJ 07936 United States of America, a citizen of the United States of America
- 2) Guang-Fei CHEN, 33 Preston Drive, Livingston, NJ 07039 United States of America, a citizen of the United States of America,
- 3) Baoqing GONG, c/o Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover NJ 07936 United States of America, a citizen of the United States of America;
- 4) Prasad Koteswara KAPA, c/o Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover NJ 07936 United States of America, a citizen of the United States of America;

(hereinafter "Inventor(s)"), and Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover NJ 07936, United States of America, a company organized under the laws of Delaware.

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, I/We the Inventor(s) do hereby confirm and agree that, by operation of law and/or contract, and/or by the fulfillment of any and all legal requirements regarding the transfer of employee inventions in my/our country of employment, Novartis Pharmaceuticals Corporation, is the true and lawful owner of all right, title and interest in all inventions, discoveries, patents/utility models, applications, and rights described in paragraphs (1) through (8) below.

If, however, under the laws of any country, I/We the Inventor(s) nevertheless have any ownership right, title or interest in any of the items described herein (which I/We do not believe to be the case and make no claim in or to), for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, I/We the Inventor(s) do hereby sell, assign and transfer to Novartis Pharmaceuticals Corporation and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of our right, title and interest for all countries of the world in and to

(1) all of our inventions and discoveries described in the provisional or non-provisional patent, utility model, or other application(s) entitled

SALT(S) OF 7-CYCLOPENTYL-2-(5-PIPERAZIN-1-YL-PYRIDIN-2-YLAMINO)-7H-PYRROLO[2,3-D]PYRIMIDINE-6-CARBOXYLIC ACID DIMETHYLAMIDE AND PROCESSES OF MAKING THEREOF

and filed in the Office on , 20 and accorded Application Number and/or filed as a PCT International Application on , 20 and accorded International Patent Application Number PCT/ ; and/or filed in the United States Patent and Trademark Office on 10 November 2010 and accorded Application Number 61/412,064

(2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);

(3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees or in our/my name, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

(4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);

(5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;

(6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;

(7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;

(8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said

patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by me/us if this sale, assignment and transfer had not been made.

I/We the Inventor(s) hereby authorize ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s) and Application Number(s) of said patent, utility model, or other application(s) when notified thereof.

I/We the Inventor(s) hereby covenant and agree that I/We will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE.

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment shall be governed by the laws of Delaware.

Assignment is effective as from the earliest priority date as stated above.

Executed this day of , 20 .

John Vincent CALIENNI L.S.

Witness
Print Name:

Witness
Print Name:

Executed this 22 day of October, 2011

Guang-Pei Chen

Guang-Pei CHEN L.S.

Guannan Wu

Witness Guannan Wu
Print Name:

Suzhu Chen

Witness Suzhu Chen
Print Name:

Executed this day of , 20 .

Baoping GONG L.S.

Witness
Print Name:

Witness
Print Name:

Executed this day of , 2011.

L.S.

Prasad Koteswara KAPA

Witness

Print Name:

Witness

Print Name:

Executed this 7th day of November, 2011.

Novartis Pharmaceuticals Corporation

BY

Lydia McNally

L.S.

Witness

Print Name

Linda Rubinaccio

Witness

Print name

Maureen McGee